New hope to stop Treatment-Disrupting side effect in breast cancer patients
Prevention
Not yet recruiting
This study tests whether Herombopag tablets can prevent low platelet counts (thrombocytopenia) in HER2-positive breast cancer patients receiving T-DM1 therapy. Low platelets are a common side effect that can cause bleeding risks and force treatment delays. The research will invol…
Phase: NA • Sponsor: Zhenzhen Liu • Aim: Prevention
Last updated Mar 23, 2026 15:18 UTC